Pathoclinical characteristic and treatment of rectal gastrointestinal stromal tumors (GISTs)

doi:10.3877/cma.j.issn.2095-3224.2019.03.003

Abstract

Abstract:

Rectum is the third most common site GISTs originise from. The management of rectal GISTs holds characteristics and difficulty owing to biology and anatomical location. They tending to occur in lower rectum with relatively high local recurrence rate. The application of peri-operational imatinib increase the resectability of tumor and lower recurrence rate. For rectal GIST with diameter of less than 5 cm, imatinib combined surgical resection can achieve a good therapeutic effect. At present, there is still lack of standard of diagnosis and treatment for rectal GIST worldwide. More prospective multicenter studies are needed for better understanding and management of this special entity.

Key words: Rectum, Gastrointestinal stromal tumors, Imatinib

Xinhua Zhang. Pathoclinical characteristic and treatment of rectal gastrointestinal stromal tumors (GISTs)[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2019, 08(03): 227-230.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2019.03.003

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2019/V08/I03/227

References 24

[1]	Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing [J]. PLoS One, 2011, 6(8): e20294.
[2]	Ma GL, Murphy JD, Martinez ME, et al. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study [J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(1): 298-302.
[3]	Kukar M, Kapil A, Papenfuss W, et al. Gastrointestinal stromal tumors (GISTs) at uncommon locations: a large population based analysis [J]. J Surg Oncol, 2015, 111(6): 696-701.
[4]	Yasui M, Tsujinaka T, Mori M, et al. Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data [J]. Surg Today, 2017, 47(10): 1188-1194.
[5]	Changchien CR, Wu MC, Tasi WS, et al. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immmunohistochemical stanning [J]. Dis Colon Rctum, 2004, 47(11): 1922-1929.
[6]	Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites [J]. Semin Diagn Pathol, 2006, 23(2): 70-83.
[7]	Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation [J]. Appl Immunohistochem Mol Morphol, 2005, 13(3): 205-220.
[8]	Hawkins A, Wells K, Krishnamurty D, et al. Preoperative Chemotherapy and Survival for Large Anorectal Gastrointestinal Stromal Tumors: A National Analysis of 333 Cases [J]. Ann Surg Oncol, 2017, 24(5): 1195-1201.
[9]	Cavnar, M, Wang L, Balachandran V, et al. Rectal Gastrointestinal Stromal Tumor (GIST) in the era of imatinib: Organ preservation and improved oncologic O\outcome [J]. Ann Surg Oncol, 2017, 24(13): 3972-3980.
[10]	Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors [J]. J Clin Oncol, 2004, 22(18): 3813-3825.
[11]	Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts [J]. Lancet Oncol, 2012, 13(3): 265-274.
[12]	周维霞, 丁科枫，殷国建, 等. 超声内镜对结直肠黏膜下病变的诊断价值[J]. 中国内镜杂志, 2017, 23(6): 92-97.
[13]	Li J, Ye Y, Wang J, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor [J]. Chin J Cancer Res, 2017, 29(4): 281-293.
[14]	DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J]. Lancet, 2009, 373(9669): 1097-1104.
[15]	Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial [J]. JAMA, 2012, 307(12): 1265-1272.
[16]	Li J, Gong JF, Wu AW, et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor [J]. Eur J Surg Oncol, 2011, 37(4): 319-324.
[17]	Huynh TK, Meeus P, Cassier P, et al. Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma Group[J]. BMC Cancer, 2014, 14: 156.
[18]	Liu H, Yan Z, Liao G, et al. Treatment strategy of rectal gastrointestinal stromal tumor (GIST) [J]. J Surg Oncol, 2014, 109(7): 708-713.
[19]	Wilkinson MJ, Fitzgerald JE, Strauss DC, et al. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib [J]. Br J Surg, 2015, 102(8): 965-971.
[20]	Jakob J, Mussi C, Ronellenfitsch U, et al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib [J]. Ann Surg Oncol, 2013, 20(2): 586-592.
[21]	Pai VD, Demenezes JL, Patil PS, et al. Multimodality therapy of rectal gastrointestinal stromal tumors in the era of imatinib: an Indian series [J]. J Gastrointest Oncol, 2016, 7(2): 262-268.
[22]	Tielen R, Verhoef C, van Coevorden F, et al. Surgical management of rectal gastrointestinal stromal tumors [J]. J Surg Oncol, 2013, 107(4): 320-323.
[23]	中华医学会外科学分会胃肠外科学组. 胃肠间质瘤规范化外科治疗专家共识[J]. 中国实用外科杂志, 2015, 35(6): 593-597.
[24]	中华医学会外科学分会结直肠外科学组，中华医学会外科学分会腹腔镜与内镜外科学组. 直肠癌经肛全直肠系膜切除专家共识及手术操作指南(2017版) [J]. 中国实用外科杂志, 2017, 37(9): 978-984.

Please choose a citation manager

Content to export